AI Engines For more Details: Perplexity Kagi Labs You
Depigmentation: Monobenzone works by selectively destroying melanocytes, the cells responsible for producing melanin, the pigment that gives skin its color. By reducing melanocyte activity and melanin production, monobenzone causes depigmentation of the skin, helping to even out areas of hyperpigmentation and hypopigmentation associated with vitiligo.
Vitiligo Treatment: Monobenzone is considered an effective treatment option for vitiligo, particularly in cases where the condition affects a large area of the body or is resistant to other treatments. It can help improve the cosmetic appearance of the skin by reducing the contrast between depigmented and normal skin areas.
Side Effects: Monobenzone can cause side effects such as skin irritation, redness, itching, and burning sensation, particularly during the initial stages of treatment. These side effects are usually mild and transient but may necessitate discontinuation of the medication in some cases.
Hypopigmentation: While monobenzone is effective in depigmenting areas of hyperpigmentation in vitiligo, it can also cause hypopigmentation (lightening of the skin) in treated areas. This can result in a loss of natural skin color and may be permanent in some cases.
Sun Sensitivity: Depigmented skin areas treated with monobenzone may be more sensitive to sunlight and prone to sunburn. Patients using monobenzone should take precautions to protect their skin from sun exposure, including wearing protective clothing, using sunscreen, and avoiding prolonged sun exposure, particularly during peak hours.
Psychological Impact: Vitiligo can have a significant psychological impact on affected individuals, affecting self-esteem, body image, and quality of life. While monobenzone can help improve the cosmetic appearance of the skin, it may also contribute to psychological distress, particularly if hypopigmentation occurs or if the treatment is not successful in achieving desired results.
Long-Term Use: The long-term safety and efficacy of monobenzone for the treatment of vitiligo have not been fully established. Some studies suggest that long-term use of monobenzone may increase the risk of skin atrophy, depigmentation of adjacent untreated areas, and other adverse effects. Close monitoring by a healthcare professional is recommended for individuals using monobenzone for an extended period.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 1.3 | 0.3 | 3.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 2.5 | 1.1 | 1.27 |
| Allergies | 3 | 2.2 | 0.36 |
| Allergy to milk products | 1.5 | 1.2 | 0.25 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.3 | 2.2 | 0.95 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.7 | 0.9 | 2 |
| Ankylosing spondylitis | 3.7 | 1.5 | 1.47 |
| Anorexia Nervosa | 0.4 | 1 | -1.5 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
| Asthma | 3.3 | 1.8 | 0.83 |
| Atherosclerosis | 1.4 | 0.6 | 1.33 |
| Atrial fibrillation | 1.9 | 1.8 | 0.06 |
| Autism | 5.8 | 5.1 | 0.14 |
| Autoimmune Disease | 0.9 | 0.3 | 2 |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 1.5 | 0.6 | 1.5 |
| Brain Trauma | 0.6 | 0.6 | 0 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.9 | 0.9 | 0 |
| Carcinoma | 3.3 | 1.9 | 0.74 |
| Celiac Disease | 1.1 | 3 | -1.73 |
| Cerebral Palsy | 1.2 | 0.4 | 2 |
| Chronic Fatigue Syndrome | 3.1 | 2 | 0.55 |
| Chronic Kidney Disease | 3 | 1.2 | 1.5 |
| Chronic Lyme | 0 | 0.3 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.9 | -0.13 |
| Chronic Urticaria (Hives) | 1.1 | 1 | 0.1 |
| Coagulation / Micro clot triggering bacteria | 0.8 | 0.1 | 7 |
| Cognitive Function | 1.5 | 0.6 | 1.5 |
| Colorectal Cancer | 3.4 | 1.1 | 2.09 |
| Constipation | 1.2 | 0.1 | 11 |
| Coronary artery disease | 1.8 | 1 | 0.8 |
| COVID-19 | 4.9 | 5.1 | -0.04 |
| Crohn's Disease | 4.9 | 3.4 | 0.44 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | 0.7 | 0.14 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.2 | 0.3 | 3 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 5.7 | 4.9 | 0.16 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 1.8 | 0.3 | 5 |
| Endometriosis | 2.1 | 1.1 | 0.91 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.5 | 1.7 | 0.47 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 1.4 | 0.9 | 0.56 |
| Functional constipation / chronic idiopathic constipation | 2.5 | 1.1 | 1.27 |
| gallstone disease (gsd) | 2.5 | 0.9 | 1.78 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.3 | 1 |
| Generalized anxiety disorder | 2.8 | 1.1 | 1.55 |
| Gout | 0.7 | 0.3 | 1.33 |
| Graves' disease | 1.2 | 1.9 | -0.58 |
| Gulf War Syndrome | 0.1 | 1.6 | -15 |
| Halitosis | 0.9 | 0.9 | |
| Hashimoto's thyroiditis | 2.2 | 1.5 | 0.47 |
| Heart Failure | 1.9 | 0.7 | 1.71 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.3 | 0.3 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.7 | -0.4 |
| hyperglycemia | 1.7 | 1.7 | 0 |
| Hyperlipidemia (High Blood Fats) | 1.2 | 0.3 | 3 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.4 | 2.2 | 0.55 |
| Hypothyroidism | 0.3 | 0.7 | -1.33 |
| Hypoxia | 2.3 | 0.3 | 6.67 |
| IgA nephropathy (IgAN) | 0.9 | 2.5 | -1.78 |
| Inflammatory Bowel Disease | 4.3 | 3.8 | 0.13 |
| Insomnia | 1.3 | 2 | -0.54 |
| Intelligence | 0.5 | 0.4 | 0.25 |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 4.8 | 2.7 | 0.78 |
| ischemic stroke | 1.5 | 0.9 | 0.67 |
| Liver Cirrhosis | 4.2 | 3.8 | 0.11 |
| Long COVID | 4.4 | 3.7 | 0.19 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.9 | 1.4 | -0.56 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.3 | 1 |
| ME/CFS with IBS | 0.8 | -0.8 | |
| ME/CFS without IBS | 1.4 | 1.4 | 0 |
| Menopause | 0.5 | 0.3 | 0.67 |
| Metabolic Syndrome | 4.6 | 4 | 0.15 |
| Mood Disorders | 5.8 | 4 | 0.45 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 4.1 | 1.3 | 2.15 |
| Multiple system atrophy (MSA) | 1 | 0.4 | 1.5 |
| myasthenia gravis | 0.6 | 0.6 | |
| neuropathic pain | 0.3 | 1.6 | -4.33 |
| Neuropathy (all types) | 0.7 | 0.9 | -0.29 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.7 | 2.5 | 0.48 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 7.1 | 5.8 | 0.22 |
| obsessive-compulsive disorder | 2 | 3.3 | -0.65 |
| Osteoarthritis | 1.7 | 0.9 | 0.89 |
| Osteoporosis | 1.5 | 1.7 | -0.13 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 4.3 | 3.3 | 0.3 |
| Polycystic ovary syndrome | 2.3 | 1.6 | 0.44 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 0.9 | 0.6 | 0.5 |
| Primary sclerosing cholangitis | 1.2 | 0.8 | 0.5 |
| Psoriasis | 1.5 | 1.3 | 0.15 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.9 | 2.4 | 1.04 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 3.9 | 1.6 | 1.44 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 1.9 | 1.3 | 0.46 |
| Sleep Apnea | 1.6 | 0.7 | 1.29 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.3 | 1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.2 | 4.5 |
| Stress / posttraumatic stress disorder | 2 | 1.9 | 0.05 |
| Systemic Lupus Erythematosus | 3.1 | 1.2 | 1.58 |
| Tic Disorder | 0.3 | 1.5 | -4 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.5 | 1.5 | 0.67 |
| Type 2 Diabetes | 4.6 | 3.8 | 0.21 |
| Ulcerative colitis | 2.8 | 3.1 | -0.11 |
| Unhealthy Ageing | 2.8 | 0.9 | 2.11 |
| Vitiligo | 0.9 | 0.6 | 0.5 |
